

Test	Description	Methodology	Intended Use	FDA-approved
Prosigna	50 genes	NanoString nCounter DX Analysis	Recurrence risk and molecular subtyping	Yes
Oncotype DX	21 genes	qRT-PCR	Recurrence risk	No (exempt)
MammaPrint	70 genes	Microarray	Recurrence risk	Yes
BluePrint	80 genes	Microarray	Molecular subtyping	No
TargetPrint	ER, PR, HER2	Microarray	Molecular subtyping	No
Breast Cancer Index	5 genes	qRT-PCR	Recurrence risk	No
EndoPredict	12 genes	qRT-PCR	Recurrence risk	No
Mammostrat	5 proteins	IHC	Recurrence risk	No

qRT-PCR, quantitative reverse transcription-polymerase chain reaction; IHC, immunohistochemistry; FDA, Food and Drug Administration